Louis M Staudt

List of Publications by Citations

335 papers	62,598 citations	111 h-index	250 g-index
348 ext. papers	70,687 ext. citations	13.8 avg, IF	7.17 L-index

#	Paper	IF	Citations
335	Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. *Nature*, **2000**, 403, 503-11	50.4	7592
334	The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. *New England Journal of Medicine*, **2002**, 346, 1937-47	59.2	2971
333	Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. *Blood*, **2004**, 103, 275-82	2.2	2955
332	The transcriptional program in the response of human fibroblasts to serum. *Science*, **1999**, 283, 83-7	33.3	1713
331	Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. *Nature*, **2010**, 463, 88-92	50.4	1149
330	Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. *New England Journal of Medicine*, **2004**, 351, 2159-69	59.2	1141
329	Oncogenically active MYD88 mutations in human lymphoma. *Nature*, **2011**, 470, 115-9	50.4	1068
328	Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. *New England Journal of Medicine*, **2010**, 362, 875-85	59.2	961
327	Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. *Journal of Experimental Medicine*, **2001**, 194, 1639-47	16.6	882
326	Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. *Journal of Experimental Medicine*, **2001**, 194, 1861-74	16.6	871
325	Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. *Journal of Experimental Medicine*, **2003**, 198, 851-62	16.6	869
324	A POU-domain transcription factor in early stem cells and germ cells of the mammalian embryo. *Nature*, **1990**, 345, 686-92	50.4	809
323	Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. *Cancer Cell*, **2007**, 12, 115-30	24.3	789
322	Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. *Immunity*, **2002**, 17, 51-62	32.3	789
321	Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. *New England Journal of Medicine*, **2018**, 378, 1396-1407	59.2	780
320	A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 9991-6	11.5	768
319	Control of inflammation, cytokine expression, and germinal center formation by BCL-6. *Science*, **1997**, 276, 589-92	33.3	763

318	The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. *Cancer Cell*, **2003**, 3, 185-97	24.3	751
317	Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 13520-5	11.5	746
316	XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. *Immunity*, **2004**, 21, 81-93	32.3	739
315	A lymphoid-specific protein binding to the octamer motif of immunoglobulin genes. *Nature*, **1986**, 323, 640-3	50.4	728
314	Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. *Nature Medicine*, **2015**, 21, 922-6	50.5	707
313	Toward a Shared Vision for Cancer Genomic Data. *New England Journal of Medicine*, **2016**, 375, 1109-12	59.2	707
312	Molecular diagnosis of Burkitt's lymphoma. *New England Journal of Medicine*, **2006**, 354, 2431-42	59.2	700
311	BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. *Immunity*, **2000**, 13, 199-212	32.3	697
310	Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. *Journal of Clinical Oncology*, **2012**, 30, 3452-9	2.2	669
309	Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. *Science*, **2008**, 319, 1676-9	33.3	660
308	ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. *Blood*, **2003**, 101, 4944-51	2.2	650
307	Human blood IgM "memory" B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire. *Blood*, **2004**, 104, 3647-54	2.2	612
306	Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. *Nature*, **2012**, 490, 116-20	50.4	600
305	JAKs and STATs in immunity, immunodeficiency, and cancer. *New England Journal of Medicine*, **2013**, 368, 161-70	59.2	545
304	A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. *Clinical Cancer Research*, **2009**, 15, 5494-502	12.9	507
303	A loss-of-function RNA interference screen for molecular targets in cancer. *Nature*, **2006**, 441, 106-10	50.4	496
302	IRF4 addiction in multiple myeloma. *Nature*, **2008**, 454, 226-31	50.4	477
301	Gene regulation mediated by calcium signals in T lymphocytes. *Nature Immunology*, **2001**, 2, 316-24	19.1	469

300	MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. *Nature*, **2011**, 471, 377-81	50.4	467
299	ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. *Lancet, The*, **2004**, 363, 105-11	40	465
298	Aggressive lymphomas. *New England Journal of Medicine*, **2010**, 362, 1417-29	59.2	452
297	Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. *Blood*, **2009**, 113, 6069-76	2.2	422
296	An octamer oligonucleotide upstream of a TATA motif is sufficient for lymphoid-specific promoter activity. *Nature*, **1987**, 329, 174-8	50.4	405
295	Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. *Blood*, **2014**, 123, 1214-7	2.2	404
294	Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. *Immunity*, **2006**, 25, 225-36	32.3	400
293	Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. *New England Journal of Medicine*, **2013**, 368, 1408-16	59.2	388
292	Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. *Cancer Cell*, **2012**, 21, 723-37	24.3	386
291	Oncogenic activation of NF-kappaB. *Cold Spring Harbor Perspectives in Biology*, **2010**, 2, a000109	10.2	376
290	Stereotyped and specific gene expression programs in human innate immune responses to bacteria. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 972-7	11.5	337
289	Lymphoid malignancies: the dark side of B-cell differentiation. *Nature Reviews Immunology*, **2002**, 2, 920-32	32.5	310
288	Pathogenesis of human B cell lymphomas. *Annual Review of Immunology*, **2012**, 30, 565-610	34.7	307
287	Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. *Blood*, **2005**, 106, 3183-90	2.2	304
286	Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. *Blood*, **2014**, 123, 2915-23	2.2	299
285	SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. *Haematologica*, **2009**, 94, 1555-62	6.6	299
284	Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. *Blood*, **2008**, 111, 3701-13	2.2	287
283	Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation. *Journal of Immunology*, **2004**, 173, 1158-65	5.3	287

282	Targeting pathological B cell receptor signalling in lymphoid malignancies. *Nature Reviews Drug Discovery*, **2013**, 12, 229-43	64.1	286
281	Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. *Cancer Cell*, **2004**, 5, 191-9	24.3	284
280	Identification of early replicating fragile sites that contribute to genome instability. *Cell*, **2013**, 152, 620-32	56.2	280
279	Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma. *Cancer Cell*, **2017**, 31, 833-843.e5	24.3	279
278	Signatures of the immune response. *Immunity*, **2001**, 15, 375-85	32.3	279
277	Diffuse large B-cell lymphoma-treatment approaches in the molecular era. *Nature Reviews Clinical Oncology*, **2014**, 11, 12-23	19.4	274
276	High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 2349-54	11.5	270
275	The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. *Blood*, **2011**, 117, 211-20	2.2	257
274	Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. *Blood*, **2004**, 103, 4251-8	2.2	256
273	Ribosomal protein S3: a KH domain subunit in NF-kappaB complexes that mediates selective gene regulation. *Cell*, **2007**, 131, 927-39	56.2	254
272	Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. *Lancet Oncology, The*, **2015**, 16, 541-9	21.7	251
271	MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. *Blood*, **2010**, 116, 1515-23	2.2	251
270	Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. *Blood*, **2002**, 99, 2685-93	2.2	249
269	Low-intensity therapy in adults with Burkitt's lymphoma. *New England Journal of Medicine*, **2013**, 369, 1915-25	59.2	248
268	The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. *Blood*, **2002**, 99, 2285-90	2.2	246
267	A human protein specific for the immunoglobulin octamer DNA motif contains a functional homeobox domain. *Cell*, **1988**, 55, 135-44	56.2	239
266	BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. *Journal of Clinical Oncology*, **2006**, 24, 961-8	2.2	238
265	Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. *Journal of Clinical Oncology*, **2015**, 33, 2848-56	2.2	236

264	BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. *American Journal of Pathology*, **2004**, 165, 159-66	5.8	232
263	Cooperative epigenetic modulation by cancer amplicon genes. *Cancer Cell*, **2010**, 18, 590-605	24.3	230
262	Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. *Clinical Cancer Research*, **2005**, 11, 28-40	12.9	220
261	Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. *Science Immunology*, **2020**, 5,	28	217
260	Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. *Blood*, **2007**, 109, 271-80	2.2	211
259	Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. *Journal of Clinical Investigation*, **2009**, 119, 3395-407	15.9	207
258	Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia. *Cancer Cell*, **2012**, 22, 209-21	24.3	202
257	A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. *Cancer Cell*, **2020**, 37, 551-568.e14	24.3	194
256	Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells. *Journal of Virology*, **2004**, 78, 4108-19	6.6	194
255	Loss of signalling via G⊟13 in germinal centre B-cell-derived lymphoma. *Nature*, **2014**, 516, 254-8	50.4	192
254	Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. *Journal of Clinical Oncology*, **2019**, 37, 1285-1295	2.2	188
253	B cell super-enhancers and regulatory clusters recruit AID tumorigenic activity. *Cell*, **2014**, 159, 1524-37	56.2	186
252	Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. *Blood*, **2007**, 109, 4599-606	2.2	183
251	The biology of human lymphoid malignancies revealed by gene expression profiling. *Advances in Immunology*, **2005**, 87, 163-208	5.6	174
250	Active NF-kappaB signalling is a prerequisite for influenza virus infection. *Journal of General Virology*, **2004**, 85, 2347-2356	4.9	174
249	Toll-like receptor signaling. *Cold Spring Harbor Perspectives in Biology*, **2013**, 5, a011247	10.2	173
248	Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. *Clinical Cancer Research*, **2008**, 14, 396-404	12.9	173
247	A multiprotein supercomplex controlling oncogenic signalling in lymphoma. *Nature*, **2018**, 560, 387-391	50.4	172

246	MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma. *Blood*, **2003**, 101, 4539-46	2.2	167
245	Control of autophagic cell death by caspase-10 in multiple myeloma. *Cancer Cell*, **2013**, 23, 435-49	24.3	166
244	A library of gene expression signatures to illuminate normal and pathological lymphoid biology. *Immunological Reviews*, **2006**, 210, 67-85	11.3	165
243	Molecular diagnosis of the hematologic cancers. *New England Journal of Medicine*, **2003**, 348, 1777-85	59.2	162
242	Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. *Journal of Experimental Medicine*, **2007**, 204, 633-43	16.6	160
241	Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. *Journal of Clinical Oncology*, **2019**, 37, 1790-1799	2.2	156
240	Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 19946-51	11.5	156
239	Genomic views of the immune system*. *Annual Review of Immunology*, **2000**, 18, 829-59	34.7	152
238	The NCI Genomic Data Commons as an engine for precision medicine. *Blood*, **2017**, 130, 453-459	2.2	147
237	Oncogenic mechanisms in Burkitt lymphoma. *Cold Spring Harbor Perspectives in Medicine*, **2014**, 4,	5.4	143
236	B-cell receptor signaling in diffuse large B-cell lymphoma. *Seminars in Hematology*, **2015**, 52, 77-85	4	139
235	Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. *Nature Medicine*, **2012**, 18, 1118-22	50.5	136
234	Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. *Blood*, **2009**, 114, 826-34	2.2	136
233	BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab. *Clinical Cancer Research*, **2011**, 17, 7785-95	12.9	132
232	Congenital B cell lymphocytosis explained by novel germline CARD11 mutations. *Journal of Experimental Medicine*, **2012**, 209, 2247-61	16.6	131
231	IRF4: Immunity. Malignancy! Therapy?. *Clinical Cancer Research*, **2009**, 15, 2954-61	12.9	130
230	Blockade of oncogenic IB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 11365-70	11.5	127
229	Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. *British Journal of Haematology*, **2007**, 136, 286-93	4.5	124

228	Characterization of early stages of human B cell development by gene expression profiling. *Journal of Immunology*, **2007**, 179, 3662-71	5.3	117
227	Pathogenetic importance and therapeutic implications of NF-B in lymphoid malignancies. *Immunological Reviews*, **2012**, 246, 359-78	11.3	116
226	Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 2352-7	11.5	116
225	Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy. *Journal of Experimental Medicine*, **2015**, 212, 2189-201	16.6	112
224	Casein kinase 1alpha governs antigen-receptor-induced NF-kappaB activation and human lymphoma cell survival. *Nature*, **2009**, 458, 92-6	50.4	109
223	Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes. *Human Molecular Genetics*, **2004**, 13, 1827-37	5.6	109
222	Growth suppression by acute promyelocytic leukemia-associated protein PLZF is mediated by repression of c-myc expression. *Molecular and Cellular Biology*, **2003**, 23, 9375-88	4.8	109
221	Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 13447-54	11.5	105
220	Gain-of-function CCR4 mutations in adult T cell leukemia/lymphoma. *Journal of Experimental Medicine*, **2014**, 211, 2497-505	16.6	105
219	Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. *Blood*, **2010**, 116, 953-61	2.2	105
218	Malignant pirates of the immune system. *Nature Immunology*, **2011**, 12, 933-40	19.1	104
217	TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. *Cancer Discovery*, **2013**, 3, 564-77	24.4	103
216	Gene expression profiling of lymphoid malignancies. *Annual Review of Medicine*, **2002**, 53, 303-18	17.4	101
215	Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms. *Cancer Discovery*, **2014**, 4, 480-93	24.4	100
214	Circulating human B cells that express surrogate light chains and edited receptors. *Nature Immunology*, **2000**, 1, 207-13	19.1	100
213	Janus kinase deregulation in leukemia and lymphoma. *Immunity*, **2012**, 36, 529-41	32.3	99
212	Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma. *Haematologica*, **2011**, 96, 558-66	6.6	99
211	Genomic-scale gene expression profiling of normal and malignant immune cells. *Current Opinion in Immunology*, **2000**, 12, 219-25	7.8	99

210	A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *Clinical Cancer Research*, **2017**, 23, 4127-4137	12.9	98
209	Identification of a proliferation signature related to survival in nodal peripheral T-cell lymphomas. *Journal of Clinical Oncology*, **2007**, 25, 3321-9	2.2	97
208	Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP. *Journal of Clinical Oncology*, **2013**, 31, 4520-8	2.2	93
207	The molecular and cellular origins of Hodgkin's disease. *Journal of Experimental Medicine*, **2000**, 191, 207-12	16.6	90
206	Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells. *Blood*, **2003**, 101, 4576-82	2.2	89
205	Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. *Blood*, **2014**, 123, 1681-90	2.2	87
204	Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma. *Blood*, **2015**, 125, 1137-45	2.2	87
203	Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. *Blood*, **2019**, 133, 1664-1676	2.2	87
202	A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm. *Cancer Cell*, **2016**, 30, 764-778	24.3	84
201	The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study. *Blood*, **2012**, 120, 686-686	2.2	84
200	Probing lymphocyte biology by genomic-scale gene expression analysis. *Journal of Clinical Immunology*, **1998**, 18, 373-9	5.7	82
199	Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation. *Blood*, **2011**, 117, 542-52	2.2	81
198	Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis. *Blood*, **2012**, 119, 4939-48	2.2	79
197	Analysis of gamma c-family cytokine target genes. Identification of dual-specificity phosphatase 5 (DUSP5) as a regulator of mitogen-activated protein kinase activity in interleukin-2 signaling. *Journal of Biological Chemistry*, **2003**, 278, 5205-13	5.4	78
196	B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice. *Blood*, **2016**, 127, 2732-41	2.2	78
195	Transcription factor Runx2 controls the development and migration of plasmacytoid dendritic cells. *Journal of Experimental Medicine*, **2013**, 210, 2151-9	16.6	76
194	High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. *Haematologica*, **2011**, 96, 996-1001	6.6	75
193	Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma. *Blood*, **2019**, 133, 1313-1324	2.2	75

192	Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303. *Blood*, **2016**, 128, 469-469	2.2	73
191	Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt's lymphoma. *Haematologica*, **2008**, 93, 1327-34	6.6	72
190	Compensatory IKKalpha activation of classical NF-kappaB signaling during IKKbeta inhibition identified by an RNA interference sensitization screen. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 20798-803	11.5	72
189	Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma. *Cancer Cell*, **2016**, 29, 494-507	24.3	72
188	Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation. *Blood*, **2009**, 113, 2298-301	2.2	69
187	Repression of BCL-6 is required for the formation of human memory B cells in vitro. *Journal of Experimental Medicine*, **2007**, 204, 819-30	16.6	68
186	New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies. *Journal of Clinical Oncology*, **2017**, 35, 1668-1677	2.2	67
185	Dendritic cell fate is determined by BCL11A. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, E998-1006	11.5	67
184	C-myc activation impairs the NF-kappaB and the interferon response: implications for the pathogenesis of Burkitt's lymphoma. *International Journal of Cancer*, **2007**, 120, 1387-95	7.5	66
183	MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-kappa B-dependent proliferative advantage and resistance against FAS-induced cell death in B cells. *Blood*, **2005**, 105, 2891-9	2.2	65
182	Regulation of lymphocyte cell fate decisions and lymphomagenesis by BCL-6. *International Reviews of Immunology*, **1999**, 18, 381-403	4.6	64
181	MicroRNA profiles of t(14;18)-negative follicular lymphoma support a late germinal center B-cell phenotype. *Blood*, **2011**, 118, 5550-8	2.2	63
180	The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab. *American Journal of Clinical Pathology*, **2011**, 135, 54-61	1.9	60
179	Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues. *Clinical Cancer Research*, **2011**, 17, 3727-32	12.9	60
178	Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. *Blood*, **2006**, 107, 1101-7	2.2	60
177	Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profiling. *Blood*, **2012**, 119, 3757-66	2.2	56
176	A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. *Blood*, **2011**, 117, 2396-404	2.2	56
175	Chromosomal location of the octamer transcription factors, Otf-1, Otf-2, and Otf-3, defines multiple Otf-3-related sequences dispersed in the mouse genome. *Genomics*, **1991**, 10, 313-26	4.3	56

174	Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture. *Nature*, **2021**, 589, 299-305	50.4	56
173	Inhibitors of the NF-kappaB activation pathway from Cryptocarya rugulosa. *Journal of Natural Products*, **2009**, 72, 336-9	4.9	55
172	Oct-3 is a maternal factor required for the first mouse embryonic division. *Cell*, **1991**, 64, 1103-10	56.2	55
171	Gene expression physiology and pathophysiology of the immune system. *Trends in Immunology*, **2001**, 22, 35-40	14.4	54
170	A closer look at follicular lymphoma. *New England Journal of Medicine*, **2007**, 356, 741-2	59.2	53
169	Isoform-Specific Expression and Feedback Regulation of E Protein TCF4 Control Dendritic Cell Lineage Specification. *Immunity*, **2017**, 46, 65-77	32.3	52
168	Molecular diagnosis of lymphoid malignancies by gene expression profiling. *Current Opinion in Hematology*, **2002**, 9, 333-8	3.3	51
167	The human B-cell lymphoma cell line RC-K8 has multiple genetic alterations that dysregulate the Rel/NF-kappaB signal transduction pathway. *Oncogene*, **2002**, 21, 8759-68	9.2	47
166	Engagement of CD81 induces ezrin tyrosine phosphorylation and its cellular redistribution with filamentous actin. *Journal of Cell Science*, **2009**, 122, 3137-44	5.3	46
165	c-Myc and Rel/NF-kappaB are the two master transcriptional systems activated in the latency III program of Epstein-Barr virus-immortalized B cells. *Journal of Virology*, **2009**, 83, 5014-27	6.6	46
164	A B cell population that dominates the primary response to influenza virus hemagglutinin does not participate in the memory response. *European Journal of Immunology*, **1991**, 21, 2687-95	6.1	46
163	Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling. *American Journal of Surgical Pathology*, **2015**, 39, 1322-30	6.7	45
162	Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma. *Blood*, **2016**, 127, 3127-32	2.2	45
161	Targeting the HTLV-I-Regulated BATF3/IRF4 Transcriptional Network in Adult T Cell Leukemia/Lymphoma. *Cancer Cell*, **2018**, 34, 286-297.e10	24.3	44
160	Related F-box proteins control cell death in Caenorhabditis elegans and human lymphoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 3943-8	11.5	44
159	Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets. *Blood*, **2017**, 130, 1819-1831	2.2	42
158	Molecular features of B-cell lymphoma. *Current Opinion in Oncology*, **2001**, 13, 316-24	4.2	42
157	ETO family protein Mtg16 regulates the balance of dendritic cell subsets by repressing Id2. *Journal of Experimental Medicine*, **2014**, 211, 1623-35	16.6	41

156	Immune responses in mice deficient in Ly-GDI, a lymphoid-specific regulator of Rho GTPases. *Molecular Immunology*, **1997**, 34, 481-91	4.3	41
155	Pathogenic B-cell receptor signaling in lymphoid malignancies: New insights to improve treatment. *Immunological Reviews*, **2019**, 291, 190-213	11.3	40
154	Identification of FoxM1/Bub1b signaling pathway as a required component for growth and survival of rhabdomyosarcoma. *Cancer Research*, **2012**, 72, 5889-99	10.1	39
153	Clinical translation of gene expression profiling in lymphomas and leukemias. *Seminars in Oncology*, **2002**, 29, 258-63	5.5	39
152	Regulation of normal B-cell differentiation and malignant B-cell survival by OCT2. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, E2039-46	11.5	38
151	Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, E7260-E7267	11.5	37
150	Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R in MYC-Rearranged Aggressive B-Cell Lymphoma. *Blood*, **2014**, 124, 395-395	2.2	37
149	Transcriptional activation by Oct-3: evidence for a specific role of the POU-specific domain in mediating functional interaction with Oct-1. *Nucleic Acids Research*, **1996**, 24, 2112-8	20.1	34
148	Two newly characterized germinal center B-cell-associated genes, GCET1 and GCET2, have differential expression in normal and neoplastic B cells. *American Journal of Pathology*, **2003**, 163, 135-44	5.8	33
147	Frequent occurrence of deletions in primary mediastinal B-cell lymphoma. *Genes Chromosomes and Cancer*, **2007**, 46, 1090-7	5	32
146	BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma. *Human Pathology*, **2014**, 45, 2144-53	3.7	30
145	A cell-based assay for IkappaBalpha stabilization using a two-color dual luciferase-based sensor. *Assay and Drug Development Technologies*, **2007**, 5, 85-103	2.1	30
144	A novel model of controlling PD-L1 expression in ALK anaplastic large cell lymphoma revealed by CRISPR screening. *Blood*, **2019**, 134, 171-185	2.2	29
143	Protein Tyrosine Phosphatase PTPRS Is an Inhibitory Receptor on Human and Murine Plasmacytoid Dendritic Cells. *Immunity*, **2015**, 43, 277-88	32.3	27
142	Carboxyl-terminal targeting and novel post-translational processing of JAW1, a lymphoid protein of the endoplasmic reticulum. *Journal of Biological Chemistry*, **1996**, 271, 23528-34	5.4	26
141	Sharing Clinical and Genomic Data on Cancer - The Need for Global Solutions. *New England Journal of Medicine*, **2017**, 376, 2006-2009	59.2	25
140	Ibrutinib treatment of CLL: the cancer fights back. *Cancer Cell*, **2014**, 26, 11-3	24.3	25
139	The next horizon in precision oncology: Proteogenomics to inform cancer diagnosis and treatment. *Cell*, **2021**, 184, 1661-1670	56.2	25

138	Subtype-specific addiction of the activated B-cell subset of diffuse large B-cell lymphoma to FOXP1. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, E577-86	11.5	24
137	TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate. *Cell*, **2020**, 182, 297-316.e27	56.2	23
136	TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib. *Cancer Research*, **2019**, 79, 360-371	10.1	23
135	TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma. *Nature Medicine*, **2020**, 26, 577-588	50.5	22
134	Insertion of Myc into Igh accelerates peritoneal plasmacytomas in mice. *Cancer Research*, **2005**, 65, 7644-52	12.1	22
133	It's ALL in the diagnosis. *Cancer Cell*, **2002**, 1, 109-10	24.3	22
132	Towards molecular diagnosis and targeted therapy of lymphoid malignancies. *Seminars in Hematology*, **2003**, 40, 296-307	4	21
131	Phase I Study of Dose-Adjusted-Teddi-R with Ibrutinib in Untreated and Relapsed/Refractory Primary CNS Lymphoma. *Blood*, **2015**, 126, 472-472	2.2	21
130	PI3K□inhibition causes feedback activation of PI3K□ in the ABC subtype of diffuse large B-cell lymphoma. *Oncotarget*, **2017**, 8, 81794-81802	3.3	21
129	Protein ubiquitination in lymphoid malignancies. *Immunological Reviews*, **2015**, 263, 240-56	11.3	18
128	A new "brew" of MALT1 inhibitors. *Cancer Cell*, **2012**, 22, 706-7	24.3	18
127	CIITA or RFX coding region loss of function mutations occur rarely in diffuse large B-cell lymphoma cases and cell lines with low levels of major histocompatibility complex class II expression. *Haematologica*, **2009**, 94, 596-8	6.6	18
126	Focus on lymphomas. *Cancer Cell*, **2002**, 2, 363-6	24.3	18
125	Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas. *Immunity*, **2021**, 54, 116-131.e10	32.3	18
124	Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment. *Cancer Cell*, **2021**, 39, 38-53.e7	24.3	18
123	Developing Cancer Informatics Applications and Tools Using the NCI Genomic Data Commons API. *Cancer Research*, **2017**, 77, e15-e18	10.1	17
122	HSP90 promotes Burkitt lymphoma cell survival by maintaining tonic B-cell receptor signaling. *Blood*, **2017**, 129, 598-608	2.2	16
121	A roadmap for discovery and translation in lymphoma. *Blood*, **2015**, 125, 2175-7	2.2	16

120	Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFkappaB activity within two separate high-throughput screens of NFkappaB activation. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 329-35	2.9	16
119	Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. *Cancer Cell*, **2021**,	24.3	14
118	II. Therapy of DLBCL based on genomics. *Hematological Oncology*, **2013**, 31 Suppl 1, 26-8	1.3	13
117	Reliable subtype classification of diffuse large B-cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay. *Haematologica*, **2017**, 102, e404-e406	6.6	13
116	A Global, Randomized, Placebo-Controlled, Phase 3 Study of Ibrutinib Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Patients with Previously Untreated Non-Germinal Center B-Cell-like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL). *Blood*, **2018**, 132, 784-784	2.2	13
115	Lack of MYD88 L265P in non-immunoglobulin M lymphoplasmacytic lymphoma. *Leukemia and Lymphoma*, **2014**, 55, 1402-3	1.9	12
114	MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma. *Haematologica*, **2021**, 106, 2682-2693	6.6	12
113	Taming the Heterogeneity of Aggressive Lymphomas for Precision Therapy. *Annual Review of Cancer Biology*, **2019**, 3, 429-455	13.3	12
112	Diffuse large B-cell lymphoma cell-of-origin classification using the Lymph2Cx assay in the context of BCL2 and MYC expression status. *Leukemia and Lymphoma*, **2016**, 57, 717-20	1.9	11
111	ATM deficiency promotes development of murine B-cell lymphomas that resemble diffuse large B-cell lymphoma in humans. *Blood*, **2015**, 126, 2291-301	2.2	11
110	Genome-wide methylation analyses identify a subset of mantle cell lymphoma with a high number of methylated CpGs and aggressive clinicopathological features. *International Journal of Cancer*, **2013**, 133, 2852-63	7.5	11
109	Primary Mediastinal Large B-Cell Lymphoma (PMBL) Outcome Is Significantly Improved by the Addition of Rituximab to Dose Adjusted (DA)-EPOCH and Overcomes the Need for Radiation.. *Blood*, **2005**, 106, 929-929	2.2	11
108	A Phase 2/3 Multicenter, Randomized Study Comparing the Efficacy and Safety of Lenalidomide Versus Investigator Choice in Relapsed/Refractory DLBCL. *Blood*, **2014**, 124, 628-628	2.2	11
107	The NCI Genomic Data Commons. *Nature Genetics*, **2021**, 53, 257-262	36.3	11
106	Toward best practice in cancer mutation detection with whole-genome and whole-exome sequencing. *Nature Biotechnology*, **2021**, 39, 1141-1150	44.5	11
105	BCL-6 and rituximab in diffuse large B-cell lymphoma: where are we?. *Blood*, **2007**, 109, 843-4; discussion 844-5	2.2	10
104	The Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 Modulates Chronic Active BCR Signaling and Induces Tumor Regression in Relapsed/Refractory ABC DLBCL. *Blood*, **2011**, 118, 2716-2716	2.2	10
103	Secondary Metabolites from the Fungus Dictyosporium sp. and Their MALT1 Inhibitory Activities. *Journal of Natural Products*, **2019**, 82, 154-162	4.9	10

102	Regulation of B cell receptor-dependent NF-B signaling by the tumor suppressor KLHL14. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 6092-6102	11.5	9
101	Decreased major histocompatibility complex class II expression in diffuse large B-cell lymphoma does not correlate with CpG methylation of class II transactivator promoters III and IV. *Leukemia and Lymphoma*, **2009**, 50, 1875-8	1.9	9
100	Molecular definition of the germinal centre stage of B-cell differentiation. *Philosophical Transactions of the Royal Society B: Biological Sciences*, **2001**, 356, 83-9	5.8	9
99	Gene Expression Differences between Low and High Stage Diffuse Large B Cell Lymphoma (DLBCL).. *Blood*, **2006**, 108, 809-809	2.2	9
98	Comparative Clinical and Biological Features of Primary Mediastinal B-Cell Lymphoma (PMBL) and Mediastinal Grey Zone Lymphoma (MGZL).. *Blood*, **2009**, 114, 106-106	2.2	9
97	IRAK4 Kinase As A Novel Therapeutic Target in the ABC Subtype of Diffuse Large B Cell Lymphoma. *Blood*, **2012**, 120, 62-62	2.2	9
96	Cancer: negative feedback for B cells. *Nature*, **2004**, 431, 919-20	50.4	8
95	Phase I/II study of Bortezomib Alone and Bortezomib with Dose-Adjusted EPOCH Chemotherapy in Relapsed or Refractory Aggressive B-Cell Lymphoma.. *Blood*, **2004**, 104, 1385-1385	2.2	8
94	Rewiring of B cell receptor signaling by Epstein-Barr virus LMP2A. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 26318-26327	11.5	8
93	Concurrent Expression Of MYC/BCL2 Protein In Newly Diagnosed DLBCL Is Not Associated With An Inferior Survival Following EPOCH-R Therapy. *Blood*, **2013**, 122, 3029-3029	2.2	7
92	Immunostaining to identify molecular subtypes of diffuse large B-cell lymphoma in a population-based epidemiologic study in the pre-rituximab era. *International Journal of Molecular Epidemiology and Genetics*, **2011**, 2, 245-52	0.9	7
91	Gene Expression Profiling of Mediastinal Gray Zone Lymphoma and Its Relationship to Primary Mediastinal B-cell Lymphoma and Classical Hodgkin Lymphoma. *Blood Cancer Discovery*, **2020**, 1, 155-167	7	7
90	Clinical Impact of Ibrutinib with R-CHOP in Untreated Non-GCB DLBCL Co-Expressing BCL2 and MYC Genes in the Phase 3 Phoenix Trial. *Blood*, **2019**, 134, 354-354	2.2	6
89	Gene Expression Signatures Predict Overall Survial in Diffuse Large B Cell Lymphoma Treated with Rituximab and Chop-Like Chemotherapy.. *Blood*, **2007**, 110, 348-348	2.2	6
88	Multiplexing high-content flow (HCF) and quantitative high-throughput screening (qHTS) to identify compounds capable of decreasing cell viability, activating caspase 3/7, expressing annexin V, and changing mitochondrial membrane integrity. *Current Protocols in Chemical Biology*, **2013**, 5, 195-212	1.8	6
87	Transformation of late passage insulin-like growth factor-I receptor null mouse embryo fibroblasts by SV40 T antigen. *Cancer Research*, **2006**, 66, 4233-9	10.1	5
86	Primary Mediastinal Large B-Cell Lymphoma (PMBL) Outcome May Be Significantly Improved by the Addition of Rituximab to Dose-Adjusted (DA)-EPOCH and Obviates the Need for Radiation: Results from a Prospective Study of 44 Patients.. *Blood*, **2006**, 108, 209-209	2.2	5
85	Monitoring of Circulating Tumor DNA As Minimal Residual Disease in Diffuse Large B-Cell Lymphoma. *Blood*, **2014**, 124, 139-139	2.2	5

84	Lkb1 deletion in murine B lymphocytes promotes cell death and cancer. *Experimental Hematology*, **2017**, 51, 63-70.e1	3.1	4
83	CRISPR-based technology to silence the expression of lncRNAs. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 8225-8227	11.5	4
82	Dose-Adjusted EPOCH-Rituximab Is Highly Effective in the GCB and ABC Subtypes of Untreated Diffuse Large B-Cell Lymphoma.. *Blood*, **2004**, 104, 159-159	2.2	4
81	Reed-Sternberg Cell Genome Expression Supports a B-Cell Lineage. *Blood*, **1999**, 94, 411-416	2.2	4
80	Primary diffuse large B-cell lymphoma associated with clonally-related monoclonal B lymphocytosis indicates a common precursor cell. *Haematologica*, **2015**, 100, e415-8	6.6	3
79	The BCL-2 biomarker in the era of molecular diagnosis of diffuse large B-cell lymphoma. *Leukemia and Lymphoma*, **2007**, 48, 1061-3	1.9	3
78	Dose-Adjusted Teddi-R Induces Durable Complete Remissions in Relapsed and Refractory Primary CNS Lymphoma. *Blood*, **2018**, 132, 4195-4195	2.2	3
77	DA-EPOCH-R Is Highly Effective in Both BCL-6+ and BCL-6− Untreated De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Study Update and Analysis of Survival Outcomes for Multiple Biomarkers.. *Blood*, **2006**, 108, 206-206	2.2	3
76	CD28 Mutations in Peripheral T-Cell Lymphomagenesis and Progression. *Blood*, **2014**, 124, 1681-1681	2.2	3
75	Multicenter Phase 1b Dose-Escalation Study of Ibrutinib and Lenalidomide Combined with Dose-Adjusted EPOCH-R in Patients with Relapsed/Refractory DLBCL. *Blood*, **2015**, 126, 1527-1527	2.2	3
74	Overcoming Acquired Epigenetic Resistance to BTK Inhibitors. *Blood Cancer Discovery*, **2021**, 2, 630-647	7	3
73	Retraction: Oct-3 is a maternal factor required for the first mouse embryonic division. *Cell*, **1992**, 69, 724	56.2	2
72	In vivo CRISPR screens reveal a HIF-1α-mTOR-network regulates T follicular helper versus Th1 cells.. *Nature Communications*, **2022**, 13, 805	17.4	2
71	PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma. *Blood*, **2019**, 134, 2869-2869	2.2	2
70	CARD11 as an Oncogene in Diffuse Large B Cell Lymphoma.. *Blood*, **2007**, 110, 692-692	2.2	2
69	Gene Expression Signatures That Delineate Biologic and Prognostic Subgroups in Peripheral T-Cell Lymphoma. *Blood*, **2012**, 120, 679-679	2.2	2
68	DNA Sequencing-Based Monitoring Of Serum Predicts Clinical Relapse Before CT Imaging in Diffuse Large B-Cell Lymphoma. *Blood*, **2013**, 122, 1767-1767	2.2	2
67	IDH2 R172 Mutations Define a Unique Subgroup of Patients in Angioimmunoblastic T-Cell Lymphoma. *Blood*, **2014**, 124, 3580-3580	2.2	2

66	Genetic and Pharmacologic Notch4 Inhibition Synergizes with FLT3 Tyrosine Kinase Inhibition in Vitro to More Effectively Eliminate FLT3/ITD-Positive Leukemia Cells. *Blood*, **2014**, 124, 3583-3583	2.2	2
65	Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP□□brutinib. *British Journal of Haematology*, **2021**, 194, 83-91	4.5	2
64	General Biomarker Recommendations for Lymphoma. *Journal of the National Cancer Institute*, **2016**, 108,	9.7	2
63	Defining, Identifying, and Understanding "Exceptional Responders" in Oncology Using the Tools of Precision Medicine. *Cancer Journal (Sudbury, Mass.)*, **2019**, 25, 296-299	2.2	2
62	A Cyclin D1-Dependent Transcriptional Program Predicts Clinical Outcome in Mantle Cell Lymphoma. *Clinical Cancer Research*, **2021**, 27, 213-225	12.9	2
61	Linking laboratory and clinical research: the development of molecularly targeted therapeutics inside the national cancer institute center for cancer research. *Clinical Advances in Hematology and Oncology*, **2003**, 1, 302-6	0.6	2
60	Genomics & proteomics: reduce, rebuild, reveal. *Immunological Reviews*, **2006**, 210, 5-7	11.3	1
59	Analysis of gene expression in lymphoid malignancies using the Lymphochip cDNA microarray. *Nature Genetics*, **1999**, 23, 22-22	36.3	1
58	Tissue Microarray Is a Useful Tool in the Evaluation of Genes Implicated in Transformation of Follicular Lymphoma.. *Blood*, **2004**, 104, 2267-2267	2.2	1
57	Aberrant Immunoglobulin Class Switch Recombination and Switch Translocations in Activated B Cell-Like Diffuse Large B-Cell Lymphoma.. *Blood*, **2006**, 108, 356-356	2.2	1
56	OCT2 (Octamer Binding Protein 2): An Essential Role in Germinal Center B Cell Differentiation and the Achilles Heel of Derived Lymphomas.. *Blood*, **2009**, 114, 362-362	2.2	1
55	Cell-of-Origin Assignment in Diffuse Large B-Cell Lymphoma Determined By Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Has Prognostic Significance Independent of IPI and MYC/BCL2 Immunohistochemistry. *Blood*, **2014**, 124, 1624-1624	2.2	1
54	Accurate Diagnosis of Aggressive B Cell Non-Hodgkin Lymphomas Using Gene Expression Profiling of Formalin-Fixed, Paraffin-Embedded Tissues. *Blood*, **2014**, 124, 3016-3016	2.2	1
53	Burkitt Lymphoma Genome Sequencing Project (BLGSP): Introduction. *Blood*, **2016**, 128, 1760-1760	2.2	1
52	Molecular Subgroups of Peripheral T-Cell Lymphoma Evolve By Distinct Genetic Pathways. *Blood*, **2016**, 128, 4096-4096	2.2	1
51	Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma. *Blood Advances*, **2021**, 5, 5239-5257	7.8	1
50	Follicular Lymphomas with and without Translocation t(14;18) Differ in Gene Expression Profiles and Genetic Alterations.. *Blood*, **2007**, 110, 360-360	2.2	1
49	Molecular Diagnosis of the Lymphomas by Gene Expression Profiling **2006**, 110-126		1

48	Genome-wide Screens Identify Lineage- and Tumor Specific-Genes Modulating MHC-I and MHC-II Immunosurveillance in Human Lymphomas		1
47	The Mir-17~92 Cluster Enhances Cell Growth and Resistance to Chemotherapy in Mantle Cell Lymphoma by Down-Regulating PTEN, PHLPP2 and BIM. *Blood*, **2008**, 112, 373-373	2.2	1
46	Bortezomib Resistance in Mantle Cell Lymphoma Is Associated with Expression of a Plasmacytoid Differentiation Program.. *Blood*, **2009**, 114, 287-287	2.2	1
45	Combined Targeting of the MET and FGF Receptor Tyrosine Kinases Induces Sustained AML Cell Death by Preventing Compensatory Upregulation of HGF in Response to MET Kinase Inhibition. *Blood*, **2011**, 118, 1405-1405	2.2	1
44	Frequent Activating Mutations Of JAK-STAT Pathway Genes In Natural Killer Cell Lymphomas. *Blood*, **2013**, 122, 812-812	2.2	1
43	Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma. *Leukemia and Lymphoma*, **2021**, 62, 2094-2106	1.9	1
42	Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behavior. *Blood*, **2021**, 138, 1570-1582	2.2	1
41	Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory and Untreated Mantle Cell Lymphoma: Safety, Efficacy, and Molecular Analysis. *Blood*, **2021**, 138, 3537-3537	2.2	0
40	Phase 2 Study of Acalabrutinib Window Prior to Frontline Therapy in Untreated Aggressive B-Cell Lymphoma: Preliminary Results and Correlatives of Response to Acalabrutinib. *Blood*, **2021**, 138, 524-524	2.2	0
39	Structure of S1PR2-heterotrimeric G signaling complex.. *Science Advances*, **2022**, 8, eabn0067	14.3	0
38	Bill Paul: The heart of immunology. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 14117-8	11.5	
37	Reply to M. Skelin et al. *Journal of Clinical Oncology*, **2019**, 37, 2584-2585	2.2	
36	Chromatin Accessibility Profiling to Increase Diagnostic Accuracy and Refine Cell-of-Origin Classification of Mature T-Cell Lymphomas. *Blood*, **2021**, 138, 809-809	2.2	
35	Novel Genetic Subgroups Inform on Shared Pathobiology within Adult and Pediatric Burkitt Lymphoma. *Blood*, **2021**, 138, 806-806	2.2	
34	High Cyclin D1 Expression Is Associated with Increased Proliferation Rate and Decreased Survival in Mantle Cell Lymphoma (MCL) and Is Caused by Genomic Deletions and Mutations that Enhance Stability of Cyclin D1 mRNA.. *Blood*, **2004**, 104, 697-697	2.2	
33	Chromosomal Imbalances in Germinal Center B-Cell-Like and Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Influence Gene Expression Signatures and Improve Gene Expression-Based Survival Prediction(the First Two Authors Contributed Equally to This Work).. *Blood*, **2004**, 104, 415-415	2.2	
32	The Natural History of Mutated, Stage AO Chronic Lymphocytic Leukemia.. *Blood*, **2004**, 104, 954-954	2.2	
31	Biological Differences in Peripheral T-Cell Lymphomas Identified by DNA Microarrays.. *Blood*, **2005**, 106, 3012-3012	2.2	

30	Characterization of Early Human B Cell Development by Gene Expression Profiling.. *Blood*, **2006**, 108, 1352-1352	2.2
29	Structural Profiles of p53 Gene Mutations Predict Clinical Outcome in Diffuse Large B-Cell Lymphoma: An International Collaborative Study.. *Blood*, **2006**, 108, 811-811	2.2
28	Distinct Genetic Aberrations in Molecular Subtypes of Diffuse Large B Cell Lymphoma Detected by Array CGH.. *Blood*, **2007**, 110, 2631-2631	2.2
27	KLHL14 Is a Tumor Suppressor in Diffuse Large B-Cell Lymphoma. *Blood*, **2019**, 134, 2766-2766	2.2
26	Genome-Wide CRISPR Library Screening Identifies CDK6 As Genetic Vulnerability in Adult T-Cell Leukemia/Lymphoma. *Blood*, **2019**, 134, 3781-3781	2.2
25	Reponse-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Doxil, Dexamethasone, and Rituximab (TEDDI-R) in Aggressive B-Cell Lymphomas with Secondary Involvement of the CNS. *Blood*, **2019**, 134, 2875-2875	2.2
24	A Gain-of-Function CCR4 Mutations in Adult T-Cell Leukemia/Lymphoma (ATLL) Enhance the Chemotactic Abilities and PI3K/AKT Activation. *Blood*, **2014**, 124, 3566-3566	2.2
23	Cell-of-Origin Subtype Classification of Diffuse Large B-Cell Lymphoma Using the Lymph2Cx Assay Retains Relevance in the Context of BCL2 and MYC Expression Status. *Blood*, **2014**, 124, 1667-1667	2.2
22	Microrna-17~92 Cluster Upregulates NF-KB Activity Via Suppressing Multiple NF-KB Negative Regulators Mediating Ubiquitination. *Blood*, **2015**, 126, 3638-3638	2.2
21	Genome-Scale ORF Screen for Mediators of NF-B Activation in DLBCL. *Blood*, **2016**, 128, 4102-4102	2.2
20	Comprehensive Genomic Analysis of Adult Burkitt Lymphoma Identifies the B-Cell Receptor Signaling Pathway As a Potential Therapeutic Target. *Blood*, **2016**, 128, 4095-4095	2.2
19	Integrating Genomic Alterations in Diffuse Large B-Cell Lymphoma Identifies New Relevant Pathways and Potential Therapeutic Targets. *Blood*, **2016**, 128, 152-152	2.2
18	Loss of CIITA and MHC Class II Expression in Diffuse Large B-Cell Lymphoma Is Not Explained by Methylation of CIITA Promoters III and IV.. *Blood*, **2008**, 112, 1786-1786	2.2
17	Molecular Signatures Implicate Innate Immune Cells, Fibrosis, and Angiogenesis in Survival Following R-CHOP Treatment of Diffuse Large B Cell Lymphoma. *Blood*, **2008**, 112, 475-475	2.2
16	Genetic Abnormalities Involved in the Development and Progression of Follicular Lymphoma.. *Blood*, **2008**, 112, 2049-2049	2.2
15	Genome-Wide Expression Profiling Predicts Treatment Outcome in Classical Hodgkin Lymphoma. *Blood*, **2008**, 112, 520-520	2.2
14	The MMSET Histone Methyl Transferase Alters Chromatin Structure and Gene Expression in t(4;14) Multiple Myeloma Cells.. *Blood*, **2009**, 114, 675-675	2.2
13	Accurate Classification of Diffuse Large B Cell Lymphoma Into Germinal Center and Activated B Cell Subtypes Using a Nuclease Protection Assay On Formalin Fixed Paraffin Embedded Tissue: A Study From the Lymphoma and Leukemia Molecular Profiling Project.. *Blood*, **2009**, 114, 620-620	2.2

12	MYC Translocations and Expression Are Clinically Important in R-CHOP Treated Patients with De Novo DLBCL.. *Blood*, **2009**, 114, 1100-1100	2.2
11	Chromosomal Alterations in Gene Expression-Defined Pediatric Aggressive B-Cell Non-Hodgkin Lymphoma (B-NHL).. *Blood*, **2009**, 114, 2922-2922	2.2
10	High Microvascular Density Correlates with Poor Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab Plus Chemotherapy (R-CT).. *Blood*, **2009**, 114, 1948-1948	2.2
9	Pathway Dependence on the Tyrosine Kinase TYK2 and Its Mediator STAT1 In T-Cell Acute Lymphoblastic Leukemia. *Blood*, **2010**, 116, 3155-3155	2.2
8	Concurrent BCL2 and MYC Protein Expression by Immunohistochemistry Determines Clinical Outcome In DLBCL Patients Treated with R-CHOP. *Blood*, **2010**, 116, 2005-2005	2.2
7	Methylation Profiling of Mediastinal Gray Zone Lymphoma Reveals a Distinctive Signature with Elements Shared by Classical Hodgkin's Lymphoma and Mediastinal Large B-Cell Lymphoma. *Blood*, **2010**, 116, 747-747	2.2
6	Aberrant Expression of Hepatocyte Growth Factor Induces Autocrine MET Activation Providing a Novel Therapeutic Target In Acute Myeloid Leukemia.. *Blood*, **2010**, 116, 1042-1042	2.2
5	Recurrent Oncogenic Mutations in CCND3 in Aggressive Lymphomas. *Blood*, **2011**, 118, 435-435	2.2
4	TYK2-STAT1 Pathway Positively Regulates BCL2 Gene Expression in T-Cell Acute Lymphoblastic Leukemia. *Blood*, **2012**, 120, 1470-1470	2.2
3	High Incidence of EZH2 Mutations with Variable Mutation Load in Follicular Lymphoma and Its Consequences for EZH2 Targeted Therapy. *Blood*, **2012**, 120, 545-545	2.2
2	Genetic Abnormalities in Follicular Lymphoma and Transformed Follicular Lymphoma.. *Blood*, **2012**, 120, 2648-2648	2.2
1	Determining Cell-Of-Origin Subtypes In Diffuse Large B-Cell Lymphoma Using Gene Expression Profiling On Formalin-Fixed Paraffin-Embedded Tissue An L.L.M.P.P. Project. *Blood*, **2013**, 122, 73-73	2.2